Adragos Pharma at CPHI Milan 2026: End-to-End Small Molecule CDMO With a Global Facility Network

A CDMO Built Around the Complexity of Small Molecule Finished Dosage Forms

Adragos Pharma is a contract development and manufacturing organization headquartered in Munich, Germany, with a deliberate focus on small molecule finished dosage forms. Rather than operating as a generalist CDMO, the company has structured its capabilities and facility network around the specific technical and regulatory demands of this segment.

The company's service model is designed to accompany pharmaceutical and biotechnology clients from early formulation work through to commercial GMP manufacturing without requiring a change of partner. Formulation and process development, analytical development, stability studies, clinical manufacturing, and full-scale GMP production are all available within the same organization. That continuity matters for complex molecules, where accumulated process knowledge is a genuine asset at each stage of development.

Adragos Pharma's global facility network spans Germany, France, Greece, Japan, and Switzerland, a footprint that gives clients geographic optionality for supply and supports the regulatory submissions required for major markets. The company holds compliance with FDA, EMA, and PMDA standards, meaning a product developed through Adragos Pharma can be positioned for the United States, European Union, and Japanese markets under a single CDMO relationship. Specialist capabilities including cold chain management and narcotics handling extend the range of programs the company can support.

For sponsors managing complex small molecule programs, the ability to carry a product from formulation development through commercial manufacturing without a technology transfer to a new partner is a meaningful risk reduction.TradeShowIntel Editorial

Who Should Be Talking to Adragos Pharma at CPHI Milan

Adragos Pharma's positioning is specific. The company serves a defined segment of the pharmaceutical market, and the fit is clearest for organizations with programs that match those parameters. The following criteria are drawn directly from the company's stated capabilities and service scope.

This assessment is based on publicly available company information and exhibitor data. Buyers should verify current capacity and service scope directly with Adragos Pharma at the show or via their website.

Services and Capabilities on Display at Fiera Milano

Adragos Pharma's presence at CPHI Worldwide Milan 2026 is an opportunity to engage directly with the team behind the company's CDMO offering. The categories below reflect the service areas the company is positioned to discuss at the event.

End-to-End Drug Development and Manufacturing Services

View image ↗

Adragos Pharma's core offering is a fully integrated CDMO service covering the complete lifecycle of a small molecule finished dosage form program. The service begins with formulation and process development, the stage at which the physical and chemical characteristics of a drug product are defined, and extends through analytical development, stability studies, clinical manufacturing, and commercial GMP production.

By maintaining this full scope within a single organization, Adragos Pharma reduces the number of technology transfers a sponsor must manage. Each transfer between development and manufacturing partners carries risk; keeping the program in-house across stages preserves process knowledge and can compress overall timelines.

Sterile, Semi-Solid, and Non-Sterile Liquid Formulations

View image ↗

Within its finished dosage form focus, Adragos Pharma covers three formulation types that represent distinct manufacturing environments and regulatory requirements: sterile formulations, semi-solid forms such as creams and gels, and non-sterile liquid preparations. The ability to handle all three within the same CDMO relationship is relevant for companies whose pipeline includes products across these categories.

Sterile manufacturing in particular carries significant infrastructure and compliance requirements. Adragos Pharma's stated capabilities in this area, combined with its FDA, EMA, and PMDA compliance, position it for programs targeting regulated markets where sterile manufacturing standards are closely scrutinized.

Cold Chain Management and Narcotics Handling

View image ↗

Two specialist capabilities that differentiate Adragos Pharma from a standard finished dosage form CDMO are its cold chain management infrastructure and its narcotics handling qualification. Cold chain requirements are increasingly common across pharmaceutical programs, and managing temperature-controlled supply within the same organization that handles manufacturing reduces handoff complexity.

Narcotics handling adds a further layer of regulatory and operational complexity that many CDMOs do not support. For companies with controlled-substance programs, this capability narrows the field of viable manufacturing partners considerably.

What the Data Says About Adragos Pharma's Market Position

The following signals are drawn from publicly available company information and structured exhibitor data. They are intended to help buyers and procurement teams assess Adragos Pharma's positioning ahead of a meeting at CPHI Milan.

For pharmaceutical and biotechnology companies evaluating CDMO partners at CPHI Milan 2026, Adragos Pharma presents a combination of geographic reach, regulatory breadth, and specialist capability that is worth assessing against the specific requirements of your program. The company's focus on small molecule finished dosage forms means the team at the booth will be equipped to engage on technical detail rather than generalist positioning.

Munich-Based, Globally Networked: The Story Behind Adragos Pharma

Adragos Pharma is headquartered in Munich, Germany, a city that sits within one of Europe's most established pharmaceutical and life sciences corridors. The company operates as a contract development and manufacturing organization with a specific focus on small molecule finished dosage forms, a segment that demands precision in formulation science, rigorous analytical capability, and manufacturing infrastructure capable of meeting the standards of multiple regulatory authorities.

The company's global facility network, spanning Germany, France, Greece, Japan, and Switzerland, reflects a deliberate approach to serving international clients across different regulatory jurisdictions. Rather than directing all manufacturing through a single site, Adragos Pharma has built a distributed infrastructure that gives clients supply-chain options and supports the documentation requirements for FDA, EMA, and PMDA submissions. This structure positions the company to serve pharmaceutical and biotechnology clients whose programs require multi-market regulatory strategies.

Planning Your Meeting With Adragos Pharma at CPHI Milan

CPHI Worldwide runs across three full days at Fiera Milano. The schedule below provides a suggested framework for engaging with Adragos Pharma's team, based on how CPHI days typically unfold. Confirm specific session times and booth availability directly with the company before the show.

Five Questions Worth Raising With Adragos Pharma at CPHI Milan

These questions are designed to help buyers and procurement teams move beyond a general introduction and into a substantive conversation about fit. They are grounded in Adragos Pharma's stated capabilities and the practical considerations that matter when evaluating a CDMO partner.

1. Which of your five manufacturing sites is best suited to my specific dosage form and target market, and how do you allocate programs across the network?

   Understanding how Adragos Pharma assigns programs to specific facilities, and what drives those decisions, will clarify whether the network's geographic spread translates into practical benefit for your program's regulatory and supply-chain requirements.

2. How do you manage the transition between development-stage and commercial-scale manufacturing for a complex sterile formulation, and what does that process look like in terms of timeline and documentation?

   The value of an end-to-end CDMO is most visible at the development-to-manufacturing transition. Understanding how Adragos Pharma handles this stage, and what the sponsor's involvement looks like, is important for programs approaching that inflection point.

3. For a program requiring both EMA and FDA compliance, how do you structure the regulatory documentation and what is the typical timeline impact compared to a single-jurisdiction submission?

   Multi-market regulatory strategies add complexity. Adragos Pharma's stated compliance with both authorities is a starting point; understanding the practical execution, including documentation, timelines, and any additional costs, is the more useful data point.

4. What does your cold chain infrastructure look like end-to-end, and how do you handle temperature excursion events during transit between manufacturing sites and the client or distributor?

   Cold chain management is a stated capability, but the quality of that capability is in the operational detail. How excursions are detected, documented, and resolved tells you more about the reliability of the service than a general statement of capability.

5. What is your current capacity position for new programs entering development in 2026 or 2027, and how do you manage capacity allocation when multiple clients have overlapping timelines?

   Capacity availability is a practical constraint that is rarely addressed in marketing materials. Raising it directly at the show gives you an honest read on whether Adragos Pharma can realistically take on your program within your required timeline.

Finding Adragos Pharma at CPHI Worldwide Milan 2026

Connect With Adragos Pharma Before CPHI Milan

Whether you want to schedule a meeting at the show, request a capabilities overview, or start a conversation about a specific program, reaching out before CPHI Milan is the most effective way to make the most of your time on the floor. Use the options below to connect with the Adragos Pharma team.

Adragos Pharma at CPHI Milan 2026 — FAQs